Source comparison
[MK-677 Ipamorelin Cycle Research]: Protocol Comparison
The table below compares three common research protocol designs for MK-677 ipamorelin cycle studies. Each protocol targets different research questions. Baseline GH elevation versus pulsatile amplitude versus combined modulation. MK-677 Solo (Tonic Baseline) 2
This comparison does not assign a generated winner or score.
- The table below compares three common research protocol designs for MK-677 ipamorelin cycle studies. Each protocol targets different research questions. Baseline GH elevation versus pulsatile amplitude versus combined modulation.
- MK-677 Solo (Tonic Baseline)
- 25mg daily, oral, at bedtime
- None
- Sustained 24-hour IGF-1 AUC (area under curve)
- 50–80% above baseline by Week 3
- Best for studying chronic GH elevation effects on body composition and sleep architecture without complicating variables from pulsatile peaks
- Ipamorelin Solo (Pulsatile)
- 300mcg subcutaneous, 3× daily (morning, post-workout, pre-sleep)
- Peak GH amplitude at 45-minute post-injection
- 30–50% above baseline by Week 3
- Ideal for research isolating natural pulsatile GH patterns and receptor response without ghrelin pathway confounding
- Dual-Pathway Combination
- 25mg daily at bedtime
- 200mcg subcutaneous, 2× daily (post-workout, pre-sleep)
- Combined IGF-1 elevation + GH pulse amplitude at multiple timepoints
- 80–120% above baseline by Week 4
- Maximises both tonic and pulsatile GH pathways; requires more frequent blood sampling to distinguish pathway contributions; higher risk of receptor downregulation beyond 12 weeks
- Low-Dose Synergy (Extended Cycle)
- 12.5mg daily at bedtime
- 150mcg subcutaneous, 2× daily (morning, pre-sleep)
- Long-term IGF-1 maintenance across 16–24 weeks without receptor desensitisation
- 40–60% above baseline sustained through Week 20+
- Conservative approach prioritising receptor sensitivity preservation; slower onset but better suited for prolonged observation windows
- The dual-pathway protocol delivers the highest absolute IGF-1 response but introduces the most variables. Distinguishing which pathway contributed to specific outcomes (lean mass versus recovery versus metabolic shift) requires paired control arms running each compound solo. For labs new to growth hormone research, we recommend starting with MK-677 solo to establish baseline response curves before introducing ipamorelin complexity.